StockData
Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc. (ATRA) stock

ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$6.77+0.27 (+4.15%)

Close on Nov 18, 2026Market cap $67.96MP/E –Yield –

Atara Biotherapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Atara Biotherapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$50.94M. For fiscal 2025 it was -$50.94M. The highest annual figure on record is -$5.97M in fiscal 2013.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$50.94M–
FY2024Dec 31, 2024-$68.96M–
FY2023Dec 31, 2023-$194.20M–
FY2022Dec 31, 2022-$274.62M–
FY2021Dec 31, 2021-$231.10M–
FY2020Dec 31, 2020-$185.27M–
FY2019Dec 31, 2019-$241.36M–
FY2018Dec 31, 2018-$215.70M–
FY2017Dec 31, 2017-$107.73M–
FY2016Dec 31, 2016-$63.05M–
FY2015Dec 31, 2015-$37.45M–
FY2014Dec 31, 2014-$16.67M–
FY2013Dec 31, 2013-$5.97M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$5.70M–
Q3 FY2025Sep 30, 2025-$9.79M–
Q2 FY2025Jun 30, 2025-$7.32M–
Q1 FY2025Mar 31, 2025-$28.14M–
Q4 FY2024Dec 31, 2024-$24.56M–
Q3 FY2024Sep 30, 2024-$3.99M–
Q2 FY2024Jun 30, 2024-$10.67M–
Q1 FY2024Mar 31, 2024-$29.74M–
Q4 FY2023Dec 31, 2023-$50.45M–
Q3 FY2023Sep 30, 2023-$51.63M–
Q2 FY2023Jun 30, 2023-$53.30M–
Q1 FY2023Mar 31, 2023-$38.83M–
Q4 FY2022Dec 31, 2022-$56.92M–
Q3 FY2022Sep 30, 2022-$65.19M–
Q2 FY2022Jun 30, 2022-$65.38M–
Q1 FY2022Mar 31, 2022-$87.13M–
Q4 FY2021Dec 31, 2021-$36.74M–
Q3 FY2021Sep 30, 2021-$62.83M–
Q2 FY2021Jun 30, 2021-$63.64M–
Q1 FY2021Mar 31, 2021-$67.90M–
Q4 FY2020Dec 31, 2020-$4.72M–
Q3 FY2020Sep 30, 2020-$53.46M–
Q2 FY2020Jun 30, 2020-$58.71M–
Q1 FY2020Mar 31, 2020-$68.38M–
Q4 FY2019Dec 31, 2019-$61.40M–
Q3 FY2019Sep 30, 2019-$53.63M–
Q2 FY2019Jun 30, 2019-$55.33M–
Q1 FY2019Mar 31, 2019-$71.00M–
Q4 FY2018Dec 31, 2018-$61.59M–
Q3 FY2018Sep 30, 2018-$52.60M–
Q2 FY2018Jun 30, 2018-$46.88M–
Q1 FY2018Mar 31, 2018-$54.63M–
Q4 FY2017Dec 31, 2017-$34.64M–
Q3 FY2017Sep 30, 2017-$26.42M–
Q2 FY2017Jun 30, 2017-$23.44M–
Q1 FY2017Mar 31, 2017-$23.24M–
Q4 FY2016Dec 31, 2016-$22.16M–
Q3 FY2016Sep 30, 2016-$15.97M–

More Atara Biotherapeutics figures

See a number that looks wrong?